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Yellow fever virusIn October and November 2010, hospitals in northern Uganda reported patients with suspected hemorrhagic
fevers. Initial tests for Ebola viruses, Marburg virus, Rift Valley fever virus, and Crimean Congo hemorrhagic
fever virus were negative. Unbiased PCR ampliﬁcation of total RNA extracted directly from patient sera and
next generation sequencing resulted in detection of yellow fever virus and generation of 98% of the virus ge-
nome sequence. This ﬁnding demonstrated the utility of next generation sequencing and a metagenomic ap-
proach to identify an etiological agent and direct the response to a disease outbreak.nch, Centers for Disease Control
29, USA. Fax: +1 404 639 1509.
sevier Inc.© 2011 Published by Elsevier Inc.The study
Uganda is endemic formultiple hemorrhagic fever viruses, aswell as
other zoonotic and vector-borne diseases. In October 2010, Virus Spe-
cial Pathogens Branch (VSPB) of the Centers for Disease Control and
Prevention (CDC; Atlanta, USA) received reports of an unusual outbreak
occurring in the Abim, Agago, and Kitgum districts in northern Uganda.
While clinical information was limited, viral hemorrhagic fever was
suggested as a possible etiology due to reported bleeding and patient
deaths. In response, patient samples were collected and sent to the
CDC viral hemorrhagic fever laboratory at Uganda Virus Research Insti-
tute in Entebbe, Uganda.
Thirty-six clinical specimens were tested from individuals with evi-
dence of illness. Tests designed to diagnose the acute phase of Ebola
andMarburg hemorrhagic feverswere performed by PCR and/or antigen
detection ELISA (Towner et al., 2008) (Ksiazek et al., 1999a, 1999b). All
36 samples were negative, indicating that neither Ebola nor Marburg
virus was the etiologic agent of the outbreaks. A subset of 8 samples
was subsequently sent to VSPB to test for additional hemorrhagic feverviruses. All were negative for Rift Valley fever virus by PCR and IgM
ELISA, and for Crimean Congo hemorrhagic fever virus by PCR (Bird
et al., 2007; Madani et al., 2003).
Since the initial diagnostic tests for hemorrhagic fever viruses
were negative, we applied a metagenomic approach that uses next
generation sequencing (NGS) to detect pathogen genomic material
ampliﬁed directly from patient sera in an unbiased fashion. Such
methods have proven useful in identifying infectious agents that are
difﬁcult or impossible to isolate in cell culture or laboratory animals
(Su et al., 2011). No assumptions regarding the identity of the patho-
gen are made; therefore, new strains of known organisms, novel
pathogens, or agents not under suspicion as the cause of the illness
may be identiﬁed.
To increase the chance of detecting an infectious agent, samples from
patients believed to be in the acute stage of illness were chosen for study.
Samples from4 patientswhowere one day post onset of illnesswere fur-
ther analyzed using NGS. Total RNA was extracted from patient serum,
puriﬁed using RNeasy mini columns (Qiagen Corp., Valencia, USA), and
treated with DNase I (Ambion Inc., Austin, USA) for 40 min. cDNA was
generated using a random octomer primer with a 17-mer anchor se-
quence and SuperScript III (Invitrogen, Carlsbad, USA) reverse transcrip-
tase by incubating for 10 min at 25 °C, 50 min at 42 °C, and 15 min at
70 °C. Residual RNA was removed by RNase H (Sigma-Aldrich Co., St.
Louis, USA). The cDNA library was ampliﬁed with the random octomer
primer and a primerwith the 17-mer anchor sequencewith an additional
Table 1
Single nucleotide variations detected by NGS. Variants that contribute to amino acid changes are indicated. The frequency of variants and number of reads for the window are listed.
Reference position Reference Variants Allele variations Frequencies Counts Coverage Amino acid change
1484 C 2 C/T 93.4/6.6 57/4 61
2078 T 2 T/C 97.9/2.1 190/4 194
2087 T 2 T/G 97.3/2.7 178/5 183 Phe656Leu
2089 G 2 G/T 97.2/2.8 176/5 181 Gly657Val
2108 T 2 T/C 87.8/7.3 72/6 82
2145 A 2 A/G 93.5/6.5 58/4 62 Lys676Glu
2347 T 2 T/G 87.1/12.9 115/17 132 Val743Gly
2398 T 2 T/C 94.0/6.0 157/10 167 Met760Thr
2641 T 2 T/C 97.8/2.2 182/4 186 Leu841Pro
2760 CCT 2 CCT/ACC 97.9/2.1 191/4 195 Pro881Pro,Thr
2780 T 2 T/C 98.7/1.3 304/4 308
2824 T 2 T/C 93.5/6.5 257/18 275 Phe902Ser
2844 G 2 G/A 93.6/6.4 175/12 187 Gly909Ser
2956 T 2 T/A 92.5/7.5 161/13 174 Phe946Tyr
2983 T 2 T/C 89.5/10.5 162/19 181 Val955Ala
4225 G 2 G/A 61.4/38.6 43/27 70 Gly1369Glu
5143 G 2 G/A 93.3/6.7 56/4 60 Gly1675Glu
5411 T 2 T/C 96.7/3.3 384/13 397
5422 A 2 A/G 98.5/1.5 390/6 396 Glu1768Gly
5499 A 2 A/G 98.8/1.2 342/4 346 Arg1794Gly
5584 A 2 A/G 98.8/1.2 330/4 334 Glu1822Gly
5650 A 2 A/G 98.5/1.5 320/5 325 Lys1844Arg
5669 T 2 T/C 98.2/1.8 322/6 328
7127 T 2 T/C 97.7/2.3 211/5 216
7141 T 2 T/C 97.3/2.2 219/5 225 Ile2341Thr
7367 A 2 A/G 98.5/1.5 333/5 338
7382 T 2 T/G 98.8/1.2 318/4 322
7630 C 2 C/T 93.8/6.2 150/10 160 Thr2504Ile
7855 A 2 A/G 84.5/15.5 49/9 58 Lys2579Arg
9176 A 2 A/T 97.7/1.9 208/4 213
9190 G 2 G/A 98.8/1.2 325/4 329 Gly3024Asp
9292 A 2 A/G 98.8/1.2 335/4 339 Glu3058Gly
9428 T 2 T/A 97.6/2.4 162/4 166 Ser3103Arg
10236 C 2 C/A 75.9/24.1 22/7 29 His3373Asn
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and 49 cycles at 55 °C (Palacios et al., 2007). Unincorporated nucleotides
and fragments shorter than 70 nucleotides were removed using a Qiagen
MinElute column. The quality and complexity of the library fragment size
was analyzed on a BioAnalyzer 7500 labchip (Agilent Technologies, Santa
Clara, USA). Library fragments were directionally ligated to adapters for
454 NGS (Roche Diagnostics, Indianapolis, USA). Emulsion-based PCR
and pyrosequencing were carried out using GS FLX Titanium chemistry
and procedure as described by the manufacturer (Roche). NGS resulted
in an average of 564,204 sequence reads with an average length of 235
nucleotides.
The sequence reads were analyzed using a series of bioinformatic
tools. Random library ampliﬁcation and 454 sequencing primers were
removed using the Trimseq script by Mothur (Schloss et al., 2009).
After trimming, overlapping sequence reads were assembled into con-
tiguous segments (contigs) using the GS De Novo Assembler Newbler
(Roche) and CLC bio Genomics De Novo assembler (CLC bio, Aarhus,
Denmark). To determine the genomic origin of each sequence read,
contiguous and unassembled sequences were translated and compared
to the non-redundant protein database from the National Center for
Biotechnology Information using the basic local alignment search tool
(BLASTx). The sequence reads linked to a BLASTx result were parsed
into groups of taxa using the program MEtaGenome Analyzer
(MEGAN) (Huson et al., 2007).
Yellow fever virus (YFV) sequences were identiﬁed in 1 of the 4 pa-
tient serum samples tested. MEGAN analysis categorized 5 sequence
contigs as similar to the YFV genome sequence isolated from a 1961
outbreak in Ethiopia. The remaining contigs were of human origin
(500 contigs), bacteria (16 contigs), or unassigned taxa (19 contigs).
The 5 contigs aligning to YFV ranged from 828 to 3587 nucleotides in
length and created a contiguous segment spanning 98% of the YFV
RNA genome (10,441 of the 10,823 nucleotides). Additional sequence
reads were identiﬁed as YFV when mapped to the Ethiopian 1961 YFVgenome using a mapping reference assembler program (Genomics
CLC bio). In total, 0.5% (3229 out of 599,158 reads) of the sequenced pa-
tient library was identiﬁed as YFV. The reads averaged 309 nucleotides
in lengthwith an average coverage of 92 reads. A gap of 167 nucleotides
in the YFV sequence was completed using primers speciﬁc for Uganda
2010 YFV and sequenced by the traditional Sanger method. The 5′ end
of the genome was sequenced from the NGS library. We determined
the sequence of the ﬁnal ~101 nucleotides at the 3′ end of the genome
using 3′ RACE and Sanger sequencing.
NGS enables the detection of infectious pathogens directly from
clinical material by sequencing extremely large amounts of genetic
material without a bias of origin. NGS also provides extraordinary
depth of sequence coverage, which allows detection of variants in a
genome population. YFV is a positive-stranded RNA virus that gener-
ates frequent mutations upon replication. Mapping almost 3230 se-
quence reads to YFV gave an average coverage of 92 reads with a
range of 2 to 397 sequence reads over the entire genome. Sequence
variations in the library were detected using single nucleotide poly-
morphism (SNP) detection function in the CLC bio Genomics package,
with a window of 25 nucleotides and minimum average and center
base quality score of 35. With a minimum count of 4 variations per
site and at least 10 sequence reads of coverage, 34 variations in the
YFV genome were detected; 10 variants were silent nucleotide
changes yet 24 would contribute to a change in the encoded amino
acid (Table 1).
Genetic comparison of YFV isolates has previously established 2 South
American genotypes and5 genotypes fromAfrica (Lepiniec et al., 1994). A
full-length sequence for the Uganda 2010 isolate was compiled from the
consensus of NGS library reads and Sanger sequencing. YFV sequences
available from the NCBI database comprising the full-length genome (ap-
proximately 10,823 nucleotides) and sequence fragments with at least
10% of the genomewere imported into the SeaView program and aligned
using Muscle (Table 2).
Table 2
Sequences used in the phylogenetic analysis. GenBank accession number and length of
sequence included in the analysis are listed.
Name Accession Length
Angola1971 AY968064 10,823
Brazil1979 U23570 1479
BurkinaFaso1986 AY960139 1813
Cameroon1991 GU073131 1521
CAR1974 GU073130 1521
CAR1977A U52392 1320
CAR1977B U52395 1320
CAR1977C U23571 1479
CAR1985 U23573 1479
Colombia1979 U23580 1479
Ecuador1981 U23566 1479
Ethiopia1961Couma DQ235229 10823
Gambia2001 AY572535 10,862
Ghana1927Asibi AY640589 10,862
Guinea2000 AY502949 1479
IvoryCoast1973 GU073134 1431
IvoryCoast1982 U54798 10,862
IvoryCoast1995 GU073133 1485
IvoryCoast1996 GU073132 1473
IvoryCoast1999 AY603338 10,862
Kenya1993A U23569 1479
Mali1987 AY960138 1813
Peru1977 U23565 1479
Senegal1927Mayali U21056 10,862
Senegal1953 AH005112 2953
Senegal1965 U23574 1479
Senegal1976 GU073155 1521
Senegal1977 GU073156 1521
Senegal1978 GU073141 1521
Senegal1990 AY839635 1479
Senegal1993 GU073157 1487
Senegal1995A GU073161 1521
Senegal1995B GU073164 1476
Senegal1995C GU073162 1480
Senegal1995D GU073166 1521
Senegal1996A GU073142 1483
Senegal1996B GU073140 1484
Senegal2000A GU073148 1521
Senegal2000B GU073149 1485
Senegal2000C GU073146 1476
Senegal2000D GU073143 1521
Senegal2001A GU073154 1521
Senegal2001B GU073152 1521
Senegal2001C GU073151 1419
Senegal2001D GU073158 1521
Sudan2003 DQ068260 1479
Trinidad1979 AF094612 10,760
Trinidad2009 HM582851 10,236
Uganda1948a AY968065 10,823
Uganda1948B U52422 1320
Uganda1964 U23578 1479
Uganda2010 JN620362 10,820
Nigeria1986 U23572 1479
Nigeria1991 U23567 1479
Gambia1979 GU073135 1521
Mali1986 AY960138 1813
Concatenated sequences
DRC1958 AY541445 578
DRC1958 AF369697 670
Ethiopia1961Serie AY541407 574
Ethiopia1961Serie AF369674 670
Kenya1993 AY541408 516
Kenya1993 AF369676 670
Uganda1972 AY541440 571
Uganda1972 AF369696 670
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shows that the Uganda 2010 YFV belongs to the East/Central Africa
genotype and is most closely related to yellow fever viruses isolated
in the Central African Republic (CAR) in 1977 and 1985 (Fig. 1).
Among the African genotypes, the greatest diversity is betweenisolates from East Africa and West Africa, which differ by 21% at the
nucleotide level and 9% at the amino acid level using a pair-wise com-
parison. East Africa and East/Central Africa genotypes differ by 15% at
the nucleotide level. The Uganda 2010 full-length sequence differs by
8% from those of viruses in the East Africa genotype, and by 5% from
those of other members of the East/Central Africa lineage. This se-
quence divergence is within the range (1 to 5%) generally seen
among the East/Central Africa viruses. The polyproteins of YFV are
very conserved with East Africa and East/Central Africa genotypes
sharing 99% amino acid identity.
In order to gain further insight into the evolutionary history of the YF
lineages found in East Africa, a Bayesian analysis was carried out similar
to that performed in earlier YFV investigations (Sall et al., 2010). The
trees generated by Bayesian methods were identical (with minor ex-
ceptions) to those described above generated by likelihood (Fig. 1).
Bayesian analysis of virus E genes estimated that the most recent com-
mon ancestor shared by all YFVs was approximately 2187 years ago
(Fig. 1, nodes indicated in bold). This is within the estimated range
obtained in earlier analyses (Sall et al., 2010). The Angola genotype
shared a common ancestor with the East Africa and East/Central Africa
genotypes approximately 867 years ago whereas the YFVs of the East
Africa and East/Central Africa genotypes shared an ancestor 441 years
ago. These analyses indicate that the virus genetic diversity seen in
the East African region is not recently generated, but has accumulated
over several hundred years. The pattern of diversity would also suggest
that there have been multiple, independent introductions of YFV into
the human population from an endemic source as opposed to transmis-
sion from another region of Africa.
The genome of Uganda 2010 shares particular molecular elements
with viruses from the East Africa and East/Central Africa genotypes. A
previously reported threonine is present at amino acid position 21 of
NS4B in all East and East/Central Africa lineages, yet is absent in YFV
from the West Africa genotype (von Lindern et al., 2006). The NS4B
gene of Uganda 2010 also encodes a threonine at position 21 similar
to genotypes of East Africa viruses. Another distinguishing characteris-
tic of yellow fever viruses of different genotypes is the number of copies
of a 40 nucleotide repeat element in the 3′ non-coding region (3′ NCR),
called RYF. Viruses of the West Africa genotype contain 3 copies of RYF
separated by four to six nucleotides. YFV from the East and East/Central
Africa have only two RYF copies present in the ﬁrst and third positions
and YFV from South America has only one RYF in the third position
(Mutebi and Barrett, 2002) (Wang et al., 1996). Similar to the East
and East/Central Africa genotypes, the Uganda 2010 sequence contains
only two copies of RYF. There are additional 5′ and 3′ NCR nucleotide
variations in the Uganda 2010 that could potentially inﬂuence RNA
structural elements, however the complementary sequences thought
to be important for cyclization of the 5′ and 3′ NCR, as well as a pre-
dicted stem loop RNA structure at the 3′ terminal core are present as
expected (Villordo and Gamarnik, 2009).
Conclusions
YFV is a mosquito-borne ﬂavivirus. The majority of human infections
are asymptomatic, and clinical disease can vary from an undifferentiated
type fever to severe disease with hemorrhage (Monath and Barrett,
2003). Yellow fever is often difﬁcult to diagnose because its symptoms
are similar to those of other diseases such as malaria, leptospirosis, or in-
fection with other endemic ﬂavivirus infections such as Zika virus, West
Nile virus, or dengue virus. YFV infections often occur in children who
have yet to acquire immunity from exposure or vaccination (Monath,
2008). The patient from whom we identiﬁed YFV in this study was a
16-year-old schoolboy from the village of Golgotha, Aremo parish, Moru-
lem county, located in northeastern Uganda. His symptoms were
reported as headache, fever, diarrhea, vomiting blood, and cloudy urine,
but with the remarkable absence of jaundice. He arrived at the regional
hospital on November 9, 2010, and died 2 days later. The serum sample
Fig. 1. Phylogenetic analysis of yellow fever virus. The tree topology depicted was generated by maximum likelihood analysis utilizing the Genetic Algorithm for Rapid Likelihood Inference
(GARLI) using a general time reversible (GTR) substitution matrix with 6 relative rates and γ-distributed rate variation determined empirically (Zwickl, 2006). Full length virus sequences
are indicatedwith an “*”. There are sevenYFV genotypes. Depicted at the nodes are the bootstrap values of 500 replicates. In addition, time tomost recent common ancestor (TMRCA) estimates
were generated by Bayesian analysis and are indicated in bold at nodes of particular interest. Rates of nucleotide substitution and the TMRCAwere inferred using the YFV envelope gene data
and the BEAST, BEAUTi, and Tracer software packages (Drummond and Rambaut, 2007). A relaxed uncorrected exponential molecular clock was selected by comparing marginal likelihoods
generated in an initial analysis of 10,000,000 generationswith theGTRmatrix andgamma rate variationwith a constant population (log10 Bayes factors=14.33). TheMarkov chainMonteCarlo
(MCMC) was allowed to run for 100,000,000 generations to achieve convergence as assessed with Tracer.
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sequently identiﬁed as being infectedwith YFV, and theseﬁndingswill be
reported elsewhere.
In 1936, a serological survey of arboviruses reported yellow fever
immunity distributed throughout Uganda; however, there have
been only 4 human cases reported since 1941 with the most recent
case prior to this study detected in 1964 (Ellis and Barrett, 2008; Hen-
derson et al., 1970). Although YFV infections are frequently reported
in West Africa, notably in Senegal and most recently in Ivory Coast
(January 2011) and Sierra Leone (February 2011), infections in East
Africa are curiously intermittent (World Health Organization, 2011).
The scarcity of yellow fever cases in East Africa could be due tosubclinical disease, infrequent exposure to carrier mosquitoes, or
underreporting. Phylogenetic analysis relates the Uganda 2010 ge-
nome to the East/Central Africa lineage and it is most closely related
to YFV isolated in CAR in 1977 and 1985. Most yellow fever virus ge-
notypes also share common geographical locations and have been re-
ferred to as topotypes, but there are some exceptions (Deubel et al.,
1986). YFV sequences from both East Africa and East/Central Africa
genotypes circulate in Uganda. CAR is endemic to YFV classiﬁed as
both East and West African genotypes. It is interesting that neither
Uganda nor CAR has yet to experience a sizeable YFV outbreak or re-
port more than just a few human infections despite the observation of
such endemic YFV genetic diversity.
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Mountains of Sudan with an estimated 15,000 cases (Kirk, 1941). Subse-
quently, only infrequent cases of 1 to 8were reported for all of eastern Af-
rica until 1958 (Ellis and Barrett, 2008). A large outbreak of 1800 cases
occurred in theUpperNile region of Sudan in 1959 and spread into neigh-
boring Ethiopia, leading to the largest yellow fever epidemicwith 200,000
cases from 1960 to 1962. In contrast, Uganda reported only a single case
in 1941, 1952, and 1959. Additional serological studies performed in
1967–69 demonstrated Uganda to be endemic for YFV, yet only 1
human casewas reported in 1964. This case remained themost recent re-
port of a YFV human infection in Uganda until this report.
Phylogenetic analysis infers that YFV from the 1940 Sudan and 1961
Ethiopian outbreaks belong to the East/Central Africa genotype (Fig. 1).
Prior to this report, the two most recent YFV reported from Uganda: a
human case identiﬁed in 1964 and an isolate from a mosquito in 1972,
also share homology with YFV from these outbreaks. The Uganda 2010
genome sequence is more closely related to those available from virus
isolates fromCAR than of past outbreaks in East Africa aswell asmore re-
cent outbreaks in Sudan 2003. The genetic variation observed amongYFV
isolated from Uganda argues that YFV is endemic to the region, and that
circulating virus maintained in sylvatic cycles with nonhuman hosts is
being introduced into a human host at independent events.
YFV was the ﬁrst hemorrhagic fever virus to be isolated in 1927 and
was sequenced in its entirety in 1985, yet there is surprisingly little yellow
fever genomic information on isolates from previous outbreaks and
strains from different geographical locations (Lepiniec et al., 1994; Rice
et al., 1985). Indeed, there are only 25 full-length YFV sequences in the
NCBI database, including 7 sequences of YFV vaccine and 9 sequences
from human cases with an adverse event to vaccination.
Rapid pathogen detection and disease-speciﬁc intervention are cru-
cial in minimizing morbidity and mortality associated with viral hemor-
rhagic fever outbreaks. Here, we demonstrated the ability to rule out
commonly suspected viral hemorrhagic fevers in a timely manner, and
implemented an NGS approach when other diagnostic testing failed to
yield the etiologic agent of this outbreak. After the identiﬁcation of YFV,
theoutbreak teamamended the clinical patient case deﬁnition, distribut-
ed samples for yellow fever speciﬁc diagnostic testing, and began a vac-
cination campaign with the highly effective YFV vaccine 17D (Monath,
2005). The fact that YFV was not the suspected etiological agent in this
outbreak demonstrates the power of unbiasedNGS for pathogen surveil-
lance and discovery.
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